中国科学家创建了一个非遗传的CAR-T平台,即FACE,通过CD71加强细胞互动,利用林业发展局核准的材料,在抗药性病例中表现出希望,从而减少白血病复发。 Chinese scientists created a non-genetic CAR-T platform, FACE, that reduces leukemia relapse by enhancing cell interaction via CD71, using FDA-approved materials and showing promise in resistant cases.

中国科学家开发了一个新的CAR-T治疗平台,名为FACE,通过使用CD71蛋白质,不使用遗传工程,加强细胞间互动,以减少白血病复发。 Chinese scientists have developed a new CAR-T therapy platform called FACE that reduces leukemia relapse by enhancing cell-to-cell interaction using the CD71 protein, without genetic engineering. 生物模拟系统提高了CAR-威力,使小鼠能用五分之一的细胞剂量进行有效治疗,并直接针对癌症细胞进行化疗。 The biomimetic system boosts CAR-T potency, enabling effective treatment with one-fifth the cell dose in mice and targeting chemotherapy directly to cancer cells. 它与目前的制造业相容, 使用FDA批准的材料, 并显示出在多种白血病类型和抗药性病例中的希望。 It’s compatible with current manufacturing, uses FDA-approved materials, and shows promise across multiple leukemia types and resistant cases. 专家们强调了其广泛改善CAR-T疗法的潜力。 Experts highlight its potential to improve CAR-T therapy broadly.